2021 KyPQC Fall Meeting

The Here and NOWs of Neonatal Opioid Withdrawal Syndrome: Utilizing Science to Improve the Care of Infants with Antenatal Opioid Exposure

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • CNE: 1.00
  • Cost: Free
  • Release: Oct 20, 2021
  • Expires: Oct 20, 2024
  • Estimated Time to Complete:
    1 Hour(s)
  • Average User Rating:
    ( Ratings)

This is a recording from the live 3rd Annual KyPQC Conference, dated October 20-21, 2021. If you claimed credit for this session at the live meeting, you should not claim credit for this module. 


Lori A.  Devlin-Phinney Lori A. Devlin-Phinney, DO, MHA
Associate Professor, Pediatrics/Neonatology
University of Louisville School of Medicine
Louisville, Kentucky

Needs Statement

There is no nationally accepted standard approach to the assessment of and care for infants with neonatal opioid withdrawal syndrome. There is paucity of data on behavioral and neurodevelopmental outcomes for this high-risk population. Due to this there is a need for high quality timely multicenter studies that can be readily applied to clinical practice to develop a standard approach to the assessment for and treatment of infants with NOWS.  Multicenter longitudinal studies that are designed to harmonize behavioral and neurodevelopmental outcomes are needed.

Target Audience

Healthcare professionals interested in successful quality improvement initiatives that could be implemented in delivery hospitals.


Upon completion of this activity, participants will be able to:
1. Discuss the the scope of opioid use/misuse during pregnancy and its impact on the newborn infant
2. Review the NIH HEAL initiative and active research conducted through the ACT NOW Collaborative  
3. Describe how quality improvement initiatives and clinical research can be integrated to improve current knowledge in the field
4. Discuss how current research can improve the clinical care of infants with NOWS


In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


KyPQC is Supported by Cooperative Agreement number 2 NU17CE924971, funded by the Centers for Disease Control and Prevention (CDC).